There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .
[Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
OBJECTIVE To explore the safety and efficacy of intravenous iron sucrose in maintenance dialysis and to establish the optimal administration frequency and dose . METHODS One hundred and ninety-four patients on maintenance dialysis with the hemoglobin ( Hb ) level of 60 - 100 g/L and hematocrit ( Hct ) of 18 % - 30 % were r and omly divided into 2 sex , age , duration of dialysis , weekly erythropoietin dosage , and hematological parameters-matched groups : intravenous iron sucrose group ( n = 102 ) and oral medication group ( n = 92 ) . The intravenous iron sucrose group were sub-divided into 2 subgroups : ( 1 )  hemodialysis  ( HD ) subgroup receiving intravenous iron sucrose 200 mg once a week for 4 weeks and then 100 mg once a week for a further 8 weeks , and ( 2 )  peritoneal dialysis ( PD ) subgroup receiving intravenous iron sucrose 200 mg once a week for 4 weeks and then 200 mg once every other week for a further 8 weeks . The oral medication group received ferrous succinate 200 mg tid for 12 weeks . The levels of serum ferritin ( SF ) , transferrin saturation ( TSAT ) , Hb , and Hct were examined before treatment and 4 , 8 , and 12 weeks after treatment . RESULTS ( 1 ) Compared with baseline levels , the levels of Hb , Hct , SF , and TSAT significantly increased 2 weeks after treatment in the intravenous iron sucrose group , and 4 weeks after treatment in the oral medication group ( all P < 0.05 ) . ( 2 ) The Hb , Hct , SF , and TSAT levels 4 , 6 , 8 , and 12 weeks after treatment of the 2 intravenous iron sucrose subgroups were all significantly higher than those of the oral medication group ( all P < 0.05 ) . ( 3 ) The Hb , Hct , SF , and TSAT levels 12 weeks after treatment 6 , 8 , and 12 weeks after treatment were not significantly different from those 4 weeks after treatment in the intravenous iron sucrose group ( all P > 0.05 ) . ( 4 ) The response rate of the intravenous iron sucrose group was 95.09 % , significantly higher than that of the oral medication group ( 55.44 % , P < 0.05 ) . ( 5 ) The mean EPO doses 6 , 8 and 12 weeks after treatment of the intravenous iron sucrose group were significantly lower than that before treatment and those of the oral medication group ( all P < 0.05 ) . ( 6 ) The Hb , Hct , SF , and TSAT levels maintained stable during the period 6 , 8 , and 12 weeks after treatment in the intravenous iron sucrose group despite the decrease in dose and frequency . ( 7 ) The Hb , Hct , SF , and TSAT levels were significantly higher in the intravenous PD subgroup than in the intravenous HD subgroup . ( 8) No adverse event was found in the intravenous iron sucrose group , and adverse gastrointestinal effects occurred in 12 patients of the oral medication group . ( 9 ) After 12 weeks , the cost of EPO + intravenous iron sucrose was significantly higher than that of EPO + ferrous succinate . CONCLUSION Intravenous iron sucrose effectively increases the serum iron parameters and hemoglobin levels during maintenance peritoneal dialysis and is well tolerated . Infusing intravenous iron sucrose 200 mg every two weeks can maintain the serum iron parameters and hemoglobin level in maintenance peritoneal dialysis patients and n permits reduction of the required dose of EPO . However , the total cost of intravenous iron treatment is relatively high
There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .